ARGX — ARGENX SE
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1697862 ·
Belgium
Last close
$947.52
Market Cap
$58.92B
52W High
$1072.75
52W Low
$661.85
ADV30
468,412
Next earnings
2026-10-22
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 1,721,000,000 | 1,556,000,000 | 485,000,000 | 506,000,000 | — | — | — |
| Jun 2026 | 1,515,000,000 | 1,370,000,000 | 494,000,000 | 472,000,000 | 10,032,000,000 | 3,584,000,000 | 1,615,000,000 |
| Mar 2026 | 1,298,000,000 | 1,177,000,000 | 394,000,000 | 366,000,000 | — | — | — |
| Dec 2025 | 1,287,877,000 | 1,138,190,000 | 359,557,000 | 532,950,000 | 8,682,698,000 | 3,491,289,000 | 1,359,606,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$558,000,000
Inventory
$371,000,000
Receivables
$1,941,000,000
ST Investments
$1,600,000,000
EBIT TTM
$1,903,122,000
Pretax Income TTM
$1,899,294,000
Interest Exp TTM
$3,828,000
Analysts
23
Yahoo Snapshot (yfinance, live)
Total Revenue
$5,315,468,800
EBITDA
$1,612,902,016
Free Cash Flow
$761,769,024
Enterprise Value
$1,533,905,600,512
Total Cash
$5,184,000,000
Total Debt
$47,000,000
Shares Out
62,187,771
Trailing EPS
$26.21
Book Value
$5.38
ROE
23.6%
ROA
11.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,153,482,000 | 1,054,615,000 | 1,292,035,000 | 8,682,698,000 | 1,359,606,000 | 7,323,092,000 | 685,192,000 |
| Dec 2024 | 2,190,231,000 | -17,844,000 | 833,040,000 | 6,202,522,000 | 704,239,000 | 5,498,283,000 | -82,747,000 |
| Dec 2023 | 1,226,316,000 | -420,638,000 | -295,053,000 | 4,542,458,000 | 444,951,000 | 4,097,507,000 | -420,327,000 |
| Dec 2022 | 410,746,000 | -723,919,000 | -709,594,000 | 3,134,261,000 | 320,562,000 | 2,813,699,000 | -862,807,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$34.51
Max Pain — expiry 2026-12-18
max pain strike: $940.00 · spot: $941.25 · call oi: 1,992 · put oi: 2,322
Expected Move to 2026-12-18:
±$95.90
(10.19%) —
implied range
$845.35 –
$1037.15
· ATM straddle on $940.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MRNA | Moderna, Inc. | $82.56B | $206.80 | — |
| BIIB | BIOGEN INC. | $37.07B | $250.79 | — |
| RVMD | Revolution Medicines, Inc. | $35.19B | $162.69 | — |
| BNTX | BioNTech SE | $21.32B | $84.86 | — |
| NBIX | NEUROCRINE BIOSCIENCES INC | $16.79B | $165.92 | — |
News headlines (Yahoo Finance, 1h cache)
Cradle's Antibody Discovery Platform for Autoimmune Diseases Supports Scientific Mission of argenx
2026-11-17 13:00 · Yahoo
Biotech Dealmaker: Early-Stage Platforms And Tools Draw Capital As Full Buyouts Remain On The Sidelines This Week
2026-11-14 00:54 · Yahoo
argenx (ENXTBR:ARGX) Stock May Look Fully Priced Despite Its $1.15B Deal
2026-11-10 22:15 · Yahoo
Argenx to buy peptide platform in potentially billion-dollar deal
2026-11-09 16:27 · Yahoo
3 Reasons Argenx Could Be a Top Biotech Stock for the Next Decade
2026-11-09 10:04 · Yahoo
Argenx to acquire biotech firm Unnatural Products for $1.15 billion
2026-11-09 08:06 · Yahoo
Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines
2026-11-09 06:00 · Yahoo
argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities
2026-11-09 06:00 · Yahoo
argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis
2026-11-07 15:01 · Yahoo
AbCellera Biologics Targets 2027 Late-Stage Trial for Hot Flash Treatment
2026-11-16 22:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.